Get the Stockscreener App
2.78
0.36%
-0.01
Calcimedica Inc stock is traded at $2.78, with a volume of 20,744.
It is down -0.36% in the last 24 hours and down -26.46% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
See More
Previous Close:
$2.79
Open:
$2.8
24h Volume:
20,744
Relative Volume:
0.35
Market Cap:
$38.84M
Revenue:
-
Net Income/Loss:
$-20.87M
P/E Ratio:
-1.7375
EPS:
-1.6
Net Cash Flow:
$-21.21M
1W Performance:
-4.47%
1M Performance:
-26.46%
6M Performance:
+18.30%
1Y Performance:
-33.49%
1-Day Range:
$2.74
$2.80
1-Week Range:
$2.7001
$3.045
52-Week Range:
$1.42
$5.97
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
2.78 | 41.12M | 0 | -20.87M | -21.21M | -1.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Calcimedica Inc Stock (CALC) Latest News
Tools to assess CalciMedica Inc.’s risk profileEarnings Recap Summary & Real-Time Volume Analysis Alerts - Newser
Insider Buying Boosts Healthcare Stocks: Eli Lilly, Teleflex, and Calcimedica - AInvest
CalciMedica announces proposed public offering of common stock - MSN
Can a trend reversal in CalciMedica Inc. lead to recoveryPortfolio Profit Report & High Win Rate Trade Alerts - Newser
Intraday pattern recognizer results for CalciMedica Inc.Weekly Trade Summary & Weekly Hot Stock Watchlists - Newser
What indicators show strength in CalciMedica Inc.July 2025 PreEarnings & AI Enhanced Trade Execution Alerts - Newser
Can CalciMedica Inc. hit a new high this monthQuarterly Earnings Summary & Free Weekly Watchlist of Top Performers - Newser
CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 47.6% in July - Defense World
Multi asset correlation models including CalciMedica Inc.Entry Point & AI Powered Market Entry Ideas - Newser
CalciMedica’s CBO Makes a Bold Stock Purchase! - TipRanks
CalciMedica Inc. stock outlook for YEARBond Market & Weekly Momentum Stock Picks - Newser
How to use a screener to detect CalciMedica Inc. breakoutsNew Guidance & Free Safe Entry Trade Signal Reports - Newser
Real time social sentiment graph for CalciMedica Inc.Weekly Market Report & Weekly Top Gainers Alerts - Newser
What Fibonacci levels say about CalciMedica Inc. rebound2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Should you wait for a breakout in CalciMedica Inc.July 2025 Short Interest & Expert Curated Trade Setup Alerts - Newser
Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks - The Globe and Mail
CalciMedica director Roberts buys $14,708 in company stock - Investing.com
CalciMedica's Director, Eric W Roberts, Buys 5076 Shares at $2.9/Share. - AInvest
What candlestick patterns are forming on CalciMedica Inc.Market Activity Recap & Precise Swing Trade Entry Alerts - Newser
What makes CalciMedica Inc. stock price move sharply2025 Market Outlook & Daily Technical Stock Forecast Reports - Newser
CalciMedica’s CMO Makes a Bold Stock Purchase! - TipRanks
Will CalciMedica Inc. Bounce From 52 Week LowJuly 2025 Recap & Capital Efficient Trading Techniques - newsimpact.co.kr
Hebbar, CalciMedica CMO, buys $16k in CALC stock - Investing.com
Is CalciMedica Inc. Forming a Bottom Pattern2025 Market Trends & Stepwise Entry/Exit Trade Alerts - thegnnews.com
CalciMedica Inc. Outperforms Peers on Volume MetricsTrade Exit Report & Weekly High Return Stock Forecasts - newsimpact.co.kr
Is a relief rally coming for CalciMedica Inc. holders2025 Price Action Summary & Verified Technical Signals - Newser
Combining machine learning predictions for CalciMedica Inc.2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Does CalciMedica Inc. show high probability of rebound2025 AllTime Highs & Stepwise Trade Signal Implementation - Newser
Forecasting CalciMedica Inc. price range with options data2025 Big Picture & Safe Entry Momentum Tips - Newser
How much upside does CalciMedica Inc. haveWeekly Market Outlook & AI Powered Market Entry Strategies - thegnnews.com
Bollinger Bands Show Potential Breakout in CalciMedica Inc.Earnings Growth Report & Stepwise Entry and Exit Trade Signals - sundaytimes.kr
What data driven models say about CalciMedica Inc.’s future2025 Major Catalysts & Consistent Profit Alerts - Newser
Q3 Earnings Forecast for CalciMedica Issued By HC Wainwright - Defense World
How to forecast CalciMedica Inc. trends using time seriesJuly 2025 Review & Comprehensive Market Scan Reports - Newser
Is CalciMedica Inc. stock entering bullish territoryJuly 2025 Pullbacks & Low Drawdown Momentum Ideas - Newser
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calcimedica Inc Stock (CALC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hebbar Sudarshan | Chief Medical Officer |
Aug 15 '25 |
Buy |
2.79 |
4,392 |
12,267 |
51,976 |
| Hebbar Sudarshan | Chief Medical Officer |
Aug 14 '25 |
Buy |
2.58 |
1,584 |
4,095 |
47,584 |
| Stauderman Kenneth A. | Chief Scientific Officer |
Jul 28 '25 |
Buy |
3.96 |
1,000 |
3,960 |
12,944 |
| Stauderman Kenneth A. | Chief Scientific Officer |
Jul 25 '25 |
Sale |
3.65 |
1,000 |
3,650 |
0 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Jul 22 '25 |
Buy |
3.77 |
1,500 |
5,662 |
49,323 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Jul 21 '25 |
Buy |
3.37 |
1,500 |
5,055 |
47,823 |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Buy |
3.40 |
1,000 |
3,400 |
3,500 |
| WILSON ROBERT N | Director |
Jul 18 '25 |
Buy |
2.87 |
4,500 |
12,915 |
422,029 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Jul 18 '25 |
Buy |
2.88 |
2,000 |
5,760 |
46,323 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Jul 14 '25 |
Buy |
2.43 |
6,500 |
15,810 |
44,323 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):